Navigation Links
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:5/31/2009

Patients suffering from IBS-C can be affected physically, psychologically, socially, and economically.

About Chronic Constipation (CC)

As many as 23 million Americans suffer from CC and 12 million patients have sought treatment and been diagnosed. Patients with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week. The discomfort and bloating of CC significantly affects patients' quality of life by impairing their ability to work and participate in typical daily activities.

About Digestive Disease Week (DDW)

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy, and the Society for Surgery of the Alimentary Tract, DDW takes place May 30 - June 4, 2009, at McCormick Place, Chicago, IL. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. For more information, visit www.ddw.org.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. Linaclotide, the Company's first-in-class compound, is being evaluated in a comprehensive Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of develop
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
5. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
8. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
(Date:7/2/2015)... julio de 2015 BGI anunció hoy que ... alto rendimiento en Hong Kong ... (CAP). La instalación de BGI en Hong Kong ... próxima generación que recibe la certificación CAP en ... en prácticas de laboratorio clínico. Junto con el exitoso ...
(Date:7/2/2015)... -- ALPINION MEDICAL SYSTEMS Co., Ltd., announced today the ... to enhance user experience and patient care in a ... superb image quality. With advanced imaging technologies, this system ... and shared service applications. Confidence at first ... Series, the E-CUBE 15 EX provides advanced women,s health ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI recibe la acreditación del College of American Pathologists (CAP) 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3
... Niiki Pharma Inc. announced today the formation of its ... board, and will be joined by Lee Ellis M.D. and ... guidance to the company for its two first-in-class clinical stage ... mature, the Advisory Board will be expanded. ...
... From today, an innovative non-drug, ... available to all hypertensive patients on NHS prescription. RESPeRATE ... blood pressure. When used for just 15 minutes a ... demonstrated a significant, all-day blood pressure reduction beyond that ...
Cached Medicine Technology:Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists 2Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists 3NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 2NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 3NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 4
(Date:7/4/2015)... ... 2015 , ... Tyler Boden, Project Developer of Sullivan Solar ... the North American Board of Certified Energy Practitioners (NABCEP®), and is now a ... well established national certification organization for renewable energy professionals. Designation as a NABCEP ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US ... with even minimal asbestos exposure. Click here to read the complete story , ... Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice with ...
(Date:7/3/2015)... ... ... Smoothies are all the rage right now and all you need to ... Natural is proud to introduce a new line of all natural products that blend ... minerals! , Aurora is offering a variety of blends and stand-alone items to choose ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... opening is now the 19th sweetFrog store located in the Lone Star State. The ... fastest growing companies in 2014. , The store, which opened July 1 at Duke’s ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... side effect when combined with a type of medication ... of the saquinavir, one of a class of ... the progression of HIV infection. In the presence of ... 50 percent. ,For the study, nine healthy, HIV-negative ...
... treat everything from heartburn to impotence have prompted one in ... to retain critical information about the drug and possible side ... the Food and Drug Administration set up rules and made ... ads have a considerable effect -- nearly a third of ...
... Novartis' Femara (letrozole), one of a new class of ... tamoxifen in treating breast cancer in women// with advanced ... of drugs called aromatase inhibitors, which work differently to ... ,This new drug, Letrozole shrank tumors better and ...
... of old ladies are the latest mood-enhancing substances to ... those of young men may have the reverse effect. ... due to the human ability to detect the presence ... reports "New Scientist" magazine. ,Denise Chen, at ...
... A new method of treating childhood brain tumours, aimed at ... be trialled at hospitals around the US. Researchers will enrol ... childhood brain tumour – who will be treated with lower ... ,In the US, about 500 children are diagnosed ...
... long-delayed move, the Foods and Drugs Department is beginning ... without qualified pharmacists, an offence under the Indian Drugs ... sources, not only does this common practice jeopardise the ... to deal with high-risk drugs -- it also endangers ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: